GlassScriptPhysician profile
Taylor S Marshall
NPI 1174890065
$6,073.16
in general payments reported to CMS, 2019-2025
27 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $648 · 2022: $558 · 2023: $3,066 · 2024: $800 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,504 · Travel and Lodging: $1,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,504.26 |
| Travel and Lodging | $1,362.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,288.74 | 2021-2024 | Micra, Na, Linq II |
| Biosense Webster, INC. | $709.38 | 2021-2025 | Carto 3, Nuvision Ice Catheter |
| Pfizer INC. | $642.40 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $372.29 | 2021-2025 | |
| Abbott Laboratories | $359.66 | 2021-2025 | Assurity, Aveir, Cardiomems |
| Merck Sharp & Dohme LLC | $202.22 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $201.44 | 2021-2025 | Emblem Mri S-Icd, Accolade Sr, Ranger |
| Alnylam Pharmaceuticals INC. | $177.77 | 2022-2025 | Onpattro, Amvuttra |
| Cvrx, INC. | $155.74 | 2024-2025 | Barostim Neo System |
| Novo Nordisk INC | $151.26 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $125.27 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $107.37 | 2022-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $106.91 | 2021-2024 | Xarelto |
| Atricure, INC. | $73.57 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.80 | 2022-2025 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $58.85 | 2021-2024 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.28 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.11 | 2025 | |
| Esperion Therapeutics, INC. | $32.56 | 2021-2025 | Nexletol |
| Edwards Lifesciences Corporation | $27.43 | 2025 | Sapien 3 Ultra Resilia |
| Baxter Healthcare | $20.65 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Philips North America LLC | $19.10 | 2024 | (792) Multi Modality Ivus Other Systems |
| Bridgebio Pharma, INC. | $16.86 | 2025 | Attruby |
| Altathera Pharmaceuticals LLC | $15.78 | 2024 | Sotalol Hydrochloride |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $13.08 | 2023 | Inpefa |
| Preventice Services, LLC | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.